Global Erosive Esophagitis Market Anticipated to Reach US$ 21,157.27 Million by 2031

According to a recent market study published by Growth Market Reports, titled, “Global Erosive Esophagitis Market by Drug Class, Age Group, End-use, Distribution Channel, and Region: Size, Share, Trends and Opportunity Analysis, 2016-2031”, the market was valued at US$ 4,767.66 Million in 2022 and is anticipated to expand at a growth rate of 18.4% by 2031.

Get Sample Report @ https://growthmarketreports.com/request-sample/6219

Erosive esophagitis is an inflammation of the esophagus caused by the backflow of stomach acid into the esophagus, a condition known as gastroesophageal reflux disease (GERD). This backflow injures and erodes the esophageal tissues on progression. Other causes of erosive esophagitis include infections, autoimmune diseases, and the use of certain medications. The condition results in symptoms such as chest pain, difficulty swallowing, and heartburn. Treatment typically involves medications and lifestyle changes.

The treatment for erosive esophagitis typically involves a combination of medication and lifestyle changes. Medical therapy with proton pump inhibitors has been shown to be a safe and effective treatment option for erosive reflux esophagitis.

On the basis of drug class, the global erosive esophagitis market is classified as proton pump inhibitors, potassium-competitive acid blockers, histamine-2 receptor antagonists, and others. Among these drug class, the proton pump inhibitors segment holds a significant share of market in 2022 due to the high usage of the long-term management of gastroesophageal reflux diseases (GERD) including erosive esophagitis.

Based on age group, the global erosive esophagitis market is segmented into children and adults. The adults segment is estimated to expand at a significant CAGR during the forecast period, due to increasing obesity and acidity reflux among adults.

In terms of end-use, the global market is fragmented into hospitals, clinics, and others. The demand for erosive esophagitis is high in hospitals, as it has the ability to handle severe conditions and the need for specialized care.

On the basis of distribution channel, the global erosive esophagitis market is fragmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is estimated to expand at a significant CAGR during the forecast period. In patient care, patient preferences for medication safety and quality, and the convenience and accessibility of pharmacy services are some of the factors boosting the hospital pharmacies segment.

The COVID-19 pandemic disrupted the global supply chain due to lockdown measures, travel restrictions, and manufacturing disruptions. Supply chain issues led to challenges in the production and distribution of medications, causing delays in delivery and shortages in some regions. Supply chain disruptions moderately impacted the availability of essential raw materials required for manufacturing medications used in erosive esophagitis treatment.

Governments imposed various restrictions on trade and commerce, which affected various sectors. Governments imposed lockdowns during the COVID-19 pandemic across the globe, which moderately impacted the market. Manufacturing plants were labor-intensive. Thus, the majority of operations ceased, as companies implemented shifts and safe distance policies between workers to address social distancing concerns.

As per Growth Market Reports by industry analyst Pratik Pandit, “the increasing prevalence of gastroesophageal reflux disease, and changing eating habits are boosting the global erosive esophagitis market.”

Supply chain management is an essential part of any business. Supply chain contains a series of steps to get products from their original state to the customers. These steps include transforming raw materials into final products, transporting those products, and distributing them to the end-users. End-users are the final step of the supply chain. End-users of clear aligners include hospitals, and dental & orthodontal clinics.

Market Key Developments

In May 2023, HK inno.N presented research results of K-CAB at DDW 2023, the biggest global gastroenterology academic seminar. HK inno.N presented new clinical study results of K-CAB, a P-CAB drug for gastroesophageal reflux disease, at an academic seminar attended by 20,000 gastroenterologists from around the world. Three research results including the clinical study for the healing rate of short-term drug administration in erosive reflux disease patients were released through oral and poster presentation.

In November 2023, Phathom Pharmaceuticals announced FDA approval of VOQUEZNA (vonoprazan) tablets for the treatment of erosive GERD and relief of heartburn associated with erosive GERD in adults.

The players in the Global Clear Aligners Market include Camber Pharmaceuticals, Inc, DM Pharma, Haleon group of companies, HK inno.N Corporation, McNeil Consumer Pharmaceuticals Co, Pfizer Inc, Phathom Pharmaceuticals, Procter & Gamble, Soigner Pharma, Takeda Pharmaceuticals U.S.A., Inc, and Teva Pharmaceuticals USA, Inc.

Report Scope:

Target Audience:

• Supply-side: Raw material suppliers, Manufacturer and Distributors

• Demand Side: Hospitals, Clinics, and Others

• Regulatory Side: Approved regulatory bodies

• Associations and Industry Bodies: U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO)